Skip to content
Screener

D&A at other companies

KORU Medical Systems logo
KORU Medical SystemsKRMD
$210.03K+0.3%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$47.7M-4.2%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$1.25M+24.2%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$209K-15.7%
Medtronic logo
MedtronicMDT
$716M-14.8%
Medline, Inc. logo
Medline, Inc.MDLN
$256M+2.4%

Segments

By segment

See full
Medical Products & Therapies$51M+4.1%
Healthcare Systems & Technologies$24M-11.1%
Pharmaceuticals$16M0.0%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Less: Income (loss) from discontinued operations, net of tax262
Income (loss) from continuing operations(17)64
Adjustments to reconcile net income (loss) to cash flows from operations:
Depreciation and amortization237247
Deferred income taxes29(142)
Stock compensation1010
Net periodic pension and other postretirement costs(4)(8)
Other long-lived asset impairments22

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's D&A?
Baxter International (BAX) reported D&A of $237M in Q1 2026.
How has Baxter International's D&A changed year-over-year?
Baxter International's D&A decreased by 4.0% year-over-year, from $247M to $237M.
What is the long-term trend for Baxter International's D&A?
Over 4 years (2021 to 2025), Baxter International's D&A has grown at a 3.1% compound annual growth rate (CAGR), from $867M to $981M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Baxter International's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude